Movement Alert｜Merck Rises 3.06% in Regular Trading, Multiple Analyst Upgrades Continue to Boost Shares Following mRNA Cancer Vaccine Phase III Success

Market Focus

1 hour ago

On August 25, Merck rose 3.06% in regular trading, trading at $155.27 per share with turnover of $845 million. The continued rally was driven by a wave of analyst upgrades following the historic success of its personalized mRNA cancer vaccine Phase III trial developed jointly with Moderna.

On August 19, Merck and Moderna announced that the INTerpath-001 Phase III trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. Following the data release, Morgan Stanley upgraded Merck to Overweight from Equal-weight with a target price increase from $116 to $179. BMO raised its target from $142 to $170, while Daiwa upgraded to Outperform with a $143 target. The stock has now broken through its previous historical high, with the current price exceeding the analyst consensus target of $145.24. Merck and Moderna have indicated plans to engage with regulators regarding submission of the combination therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1184223225"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184223225\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184223225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 01:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184223225","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Merck Rises 3.06% in Regular Trading, Multiple Analyst Upgrades Continue to Boost Shares Following mRNA Cancer Vaccine Phase III Success","media":"Market Focus","content":"<p><p>On August 25, Merck rose 3.06% in regular trading, trading at $155.27 per share with turnover of $845 million. The continued rally was driven by a wave of analyst upgrades following the historic success of its personalized mRNA cancer vaccine Phase III trial developed jointly with Moderna.</p><p>On August 19, Merck and Moderna announced that the INTerpath-001 Phase III trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. Following the data release, Morgan Stanley upgraded Merck to Overweight from Equal-weight with a target price increase from $116 to $179. BMO raised its target from $142 to $170, while Daiwa upgraded to Outperform with a $143 target. The stock has now broken through its previous historical high, with the current price exceeding the analyst consensus target of $145.24. Merck and Moderna have indicated plans to engage with regulators regarding submission of the combination therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Merck Rises 3.06% in Regular Trading, Multiple Analyst Upgrades Continue to Boost Shares Following mRNA Cancer Vaccine Phase III Success</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Merck Rises 3.06% in Regular Trading, Multiple Analyst Upgrades Continue to Boost Shares Following mRNA Cancer Vaccine Phase III Success\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-26 01:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 25, Merck rose 3.06% in regular trading, trading at $155.27 per share with turnover of $845 million. The continued rally was driven by a wave of analyst upgrades following the historic success of its personalized mRNA cancer vaccine Phase III trial developed jointly with Moderna.</p><p>On August 19, Merck and Moderna announced that the INTerpath-001 Phase III trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. Following the data release, Morgan Stanley upgraded Merck to Overweight from Equal-weight with a target price increase from $116 to $179. BMO raised its target from $142 to $170, while Daiwa upgraded to Outperform with a $143 target. The stock has now broken through its previous historical high, with the current price exceeding the analyst consensus target of $145.24. Merck and Moderna have indicated plans to engage with regulators regarding submission of the combination therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"","article_id":"1184223225","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184223225","pubTimestamp":1787679201,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 25, Merck rose 3.06% in regular trading, trading at $155.27 per share with turnover of $845 million. The continued rally was driven by a wave of analyst upgrades following the historic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"走势警报|默沙东常规交易上涨 3.06%，mRNA 癌症疫苗 III 期成功后，多位分析师上调继续提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"On August 25, Merck rose 3.06% in regular trading, trading at $155.27 per share with turnover of $845 million. The continued rally was driven by a wave of analyst upgrades following the historic success of its personalized mRNA cancer vaccine Phase III trial developed jointly with Moderna.On August 19, Merck and Moderna announced that the INTerpath-001 Phase III trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. Following the data release, Morgan Stanley upgraded Merck to Overweight from Equal-weight with a target price increase from $116 to $179. BMO raised its target from $142 to $170, while Daiwa upgraded to Outperform with a $143 target. The stock has now broken through its previous historical high, with the current price exceeding the analyst consensus target of $145.24. Merck and Moderna have indicated plans to engage with regulators regarding submission of the combination therapy.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}